Our results show that C9 and CsA inhibited the proliferation of EGFR-mutant NSCLC CSCs more sensitively than EGFR-wild-type NSCLC CSCs, indicating that CypA inhibitors exhibit more effective antiproliferative activity against CSCs derived from NSCLC cells with increased EGFR activity. Here, EGFR is linked to non-small cell lung carcinoma.